Entera Bio (NASDAQ:ENTX) Stock Rating Upgraded by Wall Street Zen

Entera Bio (NASDAQ:ENTX) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Other analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Entera Bio presently has a consensus rating of “Hold” and an average price target of $9.00.

Entera Bio Stock Performance

ENTX stock opened at $2.87 on Friday. The company’s 50 day moving average is $1.85 and its 200 day moving average is $1.49. The stock has a market cap of $141.46 million, a price-to-earnings ratio of -8.20 and a beta of 1.37. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20.

Entera Bio (NASDAQ:ENTX) last announced its earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). As a group, sell-side analysts forecast that Entera Bio will post -0.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP boosted its stake in shares of Entera Bio by 51.9% in the 1st quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock valued at $228,000 after purchasing an additional 70,224 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 338.4% during the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock valued at $526,000 after purchasing an additional 365,441 shares during the last quarter. Superstring Capital Management LP purchased a new position in Entera Bio in the 4th quarter worth $33,000. Schonfeld Strategic Advisors LLC raised its position in Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after purchasing an additional 29,629 shares during the period. Finally, Jane Street Group LLC lifted its stake in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.